Stock Ratings / Health Care / ARCT / insiders

ENTA (20) PRLD (33) TTRX (38) CYPH (42) ⌘ Pro Terminal →

Arcturus Therapeutics Holdings Inc. (ARCT) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$11.03 -9.22% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.83

Arcturus Therapeutics Holdings Inc. (ARCT) carries a Roarable Rating of E (Strong Sell) with 25/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (25/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $313.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ARCT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ARCT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $11.03 (-9.22% 1D, market cap $313.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ARCT ranks #924 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ARCT compare to ENTA and PRLD in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ARCT carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ENTA (Enanta Pharmaceuticals Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $311.9M) and PRLD (Prelude Therapeutics Incorporated) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $309.6M). Among the 5-stock peer group, CYPH leads on earnings multiple (71.3x) while CYPH leads on capital efficiency (-23.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ARCT?

▼

Per ARCT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001768224), Arcturus Therapeutics Holdings Inc. generated $82.0M in revenue (-46.1% YoY), -$65.8M in net income, and -$74.5M in free cash flow against $271.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.83 (-1.85%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (25/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-14.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ARCT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (25/100 Composite)

🔍 WHY ARCT SCORES 25/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+9/20 pts (36% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (28% of score)

FRED Regime × Technicals: 44% of 52W Range • RSI-14 at 45.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$12.03-8.7% Next Q

Q2 (-2Q)

Grade E$10.98+2.3% Next Q

Q3 (-1Q)

Grade E$11.23-1.8% Next Q

Current

Grade E$11.03-10.7% Hist 90D α

Trajectory: E (33) → E (25)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ARCT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ARCT currently carries a cautious 25/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.52) and Max Pain ($11.58) forces dealer call-delta covering toward $18.86.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ARCT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ARCT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 25%NO 75%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

ARCT Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ARCT)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ARCT. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ARCT)

✓Walkthrough of ARCT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ARCT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +28.70%🛡️ HOLDING TREND SUPPORT

2026-11-03O $12.15H $12.15L $11.03C $11.03VOL 1.85M

RES: $22.14SUP: $10.03SMA50: $13.52SMA200: $9.04

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ARCT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ARCT Butterfly Map → + Track ARCT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -46.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ARCT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ARCT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ARCT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ARCT)

Health Care Rank #924 of 1016 ⚔️ ENTA vs ARCT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ARCT vs. ENTA, PRLD, TTRX, CYPH)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Arcturus Therapeutics Holdings Inc. (ARCT) ranks #924 by composite RQD confidence (25/100, grade E) and #510 by equity capitalization ($313.5M). Within this direct 5-issuer industry benchmark cohort, CYPH leads on earnings valuation at 71.3x trailing P/E, while CYPH leads on capital efficiency and profitability with -23.3% ROIC and — gross margin. CYPH currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with ARCT at 25/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ARCT ACTIVE Arcturus Therapeutics Holdings Inc.	E	25/100	—	—	-35.0%	-9.22%	$313.5M	Benchmark Subject
ENTA Enanta Pharmaceuticals Inc.	E	20/100	—	—	-35.0%	-3.95%	$311.9M	/enta-vs-arct →
PRLD Prelude Therapeutics Incorporated	E	33/100	—	—	-35.0%	-5.37%	$309.6M	/prld-vs-arct →
TTRX Turn Therapeutics Inc.	D-	38/100	—	—	-28.3%	-2.70%	$318.5M	/ttrx-vs-arct →
CYPH Cypherpunk Technologies Inc.	D-	42/100	71.3x	—	-23.3%	-9.97%	$321.1M	/cyph-vs-arct →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001768224

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Arcturus Therapeutics Holdings Inc. (ARCT) reported GAAP revenue of $82.0M (-46.1% vs. FY2024 revenue of $152.3M , and -50.8% cumulative change since FY2023) , GAAP net income of -$65.8M, operating cash flow of -$74.3M, and free cash flow of -$74.5M (-23.4% YoY). On the balance sheet, ARCT closed FY2025 with $271.1M in total assets against $0 in total debt (Altman Z-Score: 1.25, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$82.0M	-$65.8M	-$74.3M	-$74.5M	$271.1M	—
FY2024 (FY)	2024-12-31	$152.3M	-$80.9M	-$59.7M	-$60.4M	$344.1M	—
FY2023 (FY)	2023-12-31	$166.8M	-$29.7M	-$18.1M	-$18.1M	—	—

3. ARCT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ARCT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ARCT compare to ENTA and PRLD in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ARCT?

Where is ARCT trading relative to its 50-day, 200-day, and 52-week technical levels?

ARCT last traded at $11.03 (-9.22% on volume of 1,845,038 shares), positioning the stock -18.42% below its 50-day simple moving average ($13.52) and +22.01% above its 200-day simple moving average ($9.04). Across its 52-week range of $5.50 to $17.96, ARCT sits at the 44.4% percentile with a 14-day RSI of 45.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.65 to $12.41).

ARCT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are ARCT insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies ARCT leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: ARCT RQD Cockpit ARCT 12M Forecast ARCT Earnings & Move ARCT Dividends & DRIP ARCT Insiders & 13F ARCT Whale Options ARCT Profit Sankey ARCT News & Why

ROARABLE RATING BRIEF • RQD 25/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ARCT — Arcturus Therapeutics Holdings Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:38:03Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ARCT scores 25 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

Fundamental Cash Engine: 1 / 20. Per the RQD rating, this reflects ROIC of -35% and FCF yield of -21.57%. This is the weakest pillar and indicates the business is not currently generating returns on invested capital or free cash flow relative to its market value.
Whale 13F Flow: 9 / 20. Per the RQD rating, this reflects institutional accumulation and options positioning. This is the strongest pillar, indicating some institutional interest, though the source data does not itemize holdings.
Insider Conviction: 3 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The low score points to limited insider conviction signals in the data.
Macro Regime Fit: 7 / 20. Per the RQD rating, this reflects Beta of 1.0 and sector sensitivity. The stock's beta matches the market, so it carries market-level rather than amplified volatility exposure.
Forensic Balance Sheet: 5 / 20. Per the RQD rating, this reflects Altman Z of 1.25, Piotroski F of 2/9, and Debt/Equity of 0.5. The Altman Z and Piotroski readings are weak.

For a prospective investor evaluating the stock today, the pattern is a business with operating losses, negative free cash flow, and weak forensic signals, offset partly by institutional interest and a balance sheet with a Debt/Equity reading of 0.5. Any upside case would depend on the company reversing its cash-burn trajectory, which the source data does not show. The valuation tradeoff is that a $345.3M market capitalization is being applied to a business whose reported operating and net margins are both -60%. This analysis is educational and is not personalized financial advice.

Business

Arcturus Therapeutics Holdings Inc. is a NASDAQ-listed issuer in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry, per the profile section. The profile does not describe the company's products, customers, or revenue model. Reported revenue in the SEC financials was $82.0M for FY 2025, $152.3M for FY 2024, and $166.8M for FY 2023. Not available in source data for the specific sources of revenue.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$82.0M	$-76.3M	$-65.8M	N/A	$-74.5M	$230.9M	N/A
FY 2024	$152.3M	$-95.7M	$-80.9M	N/A	$-60.4M	$237.0M	N/A
FY 2023	$166.8M	$-78.2M	$-29.7M	N/A	$-18.1M	N/A	N/A

Per the SEC financials, revenue declined from $166.8M in FY 2023 to $82.0M in FY 2025, while operating losses remained in each reported year. Per the market data, gross margin is 0%, operating margin is -60%, net margin is -60%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 1.25 and the Piotroski F-Score is 2/9, with Debt/Equity of 0.5. Reported cash was $230.9M at FY 2025 year-end, compared with $237.0M at FY 2024 year-end.

Recent Catalysts & News Wire Analysis

Per the recent news section, the most recent item is an announcement that the company will report third-quarter financial results and provide a corporate update on November 5, 2026 (YELLOW). Other items include a TradingView estimates page, a debelegger.nl stock page, a Benzinga transcript of the Q2 2026 earnings call, a MarketBeat institutional ownership item, and a Globe and Mail item reporting a Buy from Leerink Partners (GREEN, CATALYST). The news section does not provide the content of the earnings call transcript or the Leerink rationale. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links or proprietary signals.

Risk watch items: the November 5, 2026 earnings release, which is the most immediate scheduled event, and the company's continued operating losses as shown in the financials.

Open Questions

What are the company's products, revenue sources, and clinical or commercial milestones? The profile and financials do not specify them.
What drove the decline in revenue from $166.8M in FY 2023 to $82.0M in FY 2025, and what is the path to positive operating income?
What are the debt obligations, given that the debt field is N/A for every reported period while Debt/Equity is listed as 0.5 in the RQD rating?
What are the TTM EPS, forward P/E, and EV/EBITDA, given that these fields are unavailable in the source data?
What institutional holdings, insider transactions, and analyst ratings exist beyond the single Leerink Partners Buy headline?

ARCT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Arcturus Therapeutics Holdings Inc. (ARCT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ARCT Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 18h ago

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026

Yahoo Finance report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 21h ago

Arcturus Therapeutics Holdings Inc. Estimates – NASDAQ:ARCT

TradingView report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.debelegger.nl • 1d ago

Arcturus Therapeutics Holdings (ARCT) Stock Price, Chart & Analysis

www.debelegger.nl report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

Transcript: Arcturus Therapeutics Q2 2026 Earnings Conference Call

Benzinga report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST The Globe and Mail • 1d ago

Arcturus Therapeutics (ARCT) Receives a Buy from Leerink Partners

The Globe and Mail report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Arcturus Therapeutics (ARCT) Institutional Ownership 2026 $ARCT

MarketBeat report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Two firms report the same Arcturus Therapeutics (ARCT) stake in an amended disclosure.

Stock Titan report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 1d ago

Leerink Partners maintains Outperform rating on Arcturus Therapeutics, $19 price target

TradingView report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ARCT Bull vs. Bear Conversation Board — What's Your Call at $11.03?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ARCT 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $10.69 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ARCT (E • RQD 25/100) a Buy at $12.15?

Welcome to the ARCT (Arcturus Therapeutics Holdings Inc.) Roar Pit. Current RQD Composite is 25/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $10.21 (-16.0%)

Spot @ $12.15

Pump the brakes on ARCT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ARCT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Arcturus Therapeutics Holdings Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $15.07 (+24.0%)

Spot @ $12.15

ARCT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ARCT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $12.15 (52-wk range $5.50 - $17.96), any beat on forward guidance forces shorts and underweight funds to chase.